Nonprofit buys experimental cancer drug to maintain patient access

Blood Cancer United acquired remaining supplies of a discontinued investigational cancer drug to ensure continued access for patients who had been benefiting from it—a concrete humanitarian intervention that prevents treatment interruption.

This does not prove the drug is effective or safe; it only ensures patients already in compassionate use can continue treatment. It addresses access for existing patients, not broader approval or availability.